Q3 2011

Filed Jul 13, 2011 · 10-Q · 43 days after period end · 0001178913-11-001977

Q3 2011 · 10-Q

Revenue—

Net Income

$457.37K

no prior Q3 2010 on file

EPS Diluted

-$0.01

no prior Q3 2010 on file

Operating Income-$591,477—

Operating Cash Flowderived-$588,296—

Same quarter

no prior Q3 2010 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended May 31, 2011 · filed Jul 13, 2011 · 43 d after period end

Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR